<?xml version="1.0" encoding="UTF-8"?>
<p id="Par16">Thirty-two patients with hematologic malignancies were diagnosed and recruited from June 2017 to January 2018 in our center. Median age was 37 years (range, 20−62 years). At the time of transplantation, a total of 14 patients with AML/ALL reached first or subsequent complete response (CR1, ≥CR2) with conventional therapy or salvage therapy; the other 18 patients had active disease without responding to salvage therapy including three ALL, three MDS-EB II, two CMML and ten AML patients. The overall characteristics of the patients and donors are summarized in Table 
 <xref rid="Tab1" ref-type="table">1</xref>.
</p>
